Pharmafile Logo

EULAR

- PMLiVE

Future of MHRA uncertain amid Brexit-fuelled shake up

Trade unions and regulatory experts warn that budget and staff cuts may lead to drug approval delays or the UK regulator simply rubber-stamping EMA decisions

- PMLiVE

GSK reveals plans for £400m R&D facility expansion in England

GSK has formally started the process of seeking a development partner for the expansion plans

- PMLiVE

MHRA outlines two-year delivery plan with ‘patient first’ focus

New delivery plan also outlines strategy for UK regulatory body following Brexit

- PMLiVE

eureKARE to use $60m financing to bolster next-generation European biotech companies

New company is focused on financing biotech companies and new ventures in Europe working on the microbiome and synthetic biology

- PMLiVE

UK biotech Synairgen treats first patient in phase 3 COVID-19 trial

SNG001 delivers an inhaled formulation of Interferon-beta-1a directly to the lungs

- PMLiVE

The Brexit clock is counting down and time is running out

What businesses need to know about post-Brexit immigration

- PMLiVE

Chancellor’s ‘coronavirus budget’ also pledges big R&D gains

Includes measures to help businesses disrupted by the pandemic

- PMLiVE

ReNeuron set for recovery after Woodford stake sale

Edison analyst says sale should help shares to stabilise

- PMLiVE

It’s Brexit day – now comes the really hard stuff

Months of trade negotiations between UK and EU lie ahead

- PMLiVE

Boris Johnson to unveil ‘talent visa’ for high-flying scientists

Global Talent visa due to come into effect on 20 February

- PMLiVE

UK biotech funding falls 40% between 2018 and 2019

Drop attributed to global uncertainty and Neil Woodford scandal

- PMLiVE

EU group calls for ‘targeted actions’ to mitigate impact of Brexit

Committee wants to ensure safe supply of drugs and medical devices

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links